Chimeric antigen receptor therapy for hepatocellular carcinoma - PubMed
7 hours ago
- #CAR T cell therapy
- #Immunotherapy
- #Hepatocellular carcinoma
- Chimeric antigen receptor (CAR) T cell therapy is being adapted from hematologic malignancies to solid tumors, including hepatocellular carcinoma (HCC).
- Solid tumors present challenges like limited immune cell infiltration, reduced T cell persistence, and antigen loss, leading to limited success in early clinical trials.
- Combinatorial strategies with next-generation armored CAR T cells and alternative immune cell types are renewing optimism in the field.
- HCC's unique liver microenvironment, influenced by lipid metabolism, bile acids, and gut-liver axis microbial compounds, presents distinct challenges and opportunities.
- HCC has various tumor-specific and tumor-associated antigens, allowing targeted approaches with minimal on-target/off-tumor effects.
- The review examines the current landscape of CAR T cell therapy for HCC, highlighting clinical and preclinical developments.
- HCC may be well-suited for tailored CAR-based strategies due to the liver's specific anatomical and immunological properties.